Please login to the form below

Not currently logged in
Email:
Password:

Parkinson's disease

This page shows the latest Parkinson's disease news and features for those working in and with pharma, biotech and healthcare.

Michael J. Fox Foundation and IBM reveal new AI model for Parkinsons disease

Michael J. Fox Foundation and IBM reveal new AI model for Parkinson’s disease

Researchers identified eight Parkinson’s disease states, with seven outcomes associated with terminal Parkinson’s disease. ... The researchers used machine learning algorithms to identify patterns in Parkinson’s disease patients, using data

Latest news

More from news
Approximately 41 fully matching, plus 198 partially matching documents found.

Latest Intelligence

  • Alzheimer’s disease: the search for a cure Alzheimer’s disease: the search for a cure

    We need to fast-track new treatments. As of last year, there are over 100 treatments in clinical trials for Alzheimer’s disease. ... The Dementia Consortium funds research into novel targets and treatments for dementia including Alzheimer’s disease,

  • Reaching patients and HCPs during the pandemic Reaching patients and HCPs during the pandemic

    When the pandemic hit, Esperion decided to push ahead with the March 2020 launch of Nexletol and build on the company’s existing digital infrastructure. ... Sunovion began commercial activities for Kynmobi (apomorphine HCI), a treatment for the acute,

  • The search for treatments for Parkinson’s disease The search for treatments for Parkinsons disease

    signalling a forlorn future for the Parkinson’s disease community. ... In Europe, the burden is immense, with the European Parkinson’s Disease Association, which represents 45 member groups, estimating an annual cost of 13.9bn to care for the 1.2

  • Can protein degraders unlock ‘undruggable’ drug targets? Can protein degraders unlock ‘undruggable’ drug targets?

    Now, interest is growing in a largely-untapped approach to targeting disease-associated proteins, particularly those that for many years have been considered ‘undruggable’. ... C4 also has a collaboration in place with Biogen focusing on neurological

  • Case study: What we're made of Case study: What we're made of

    If we don’t drink enough water, it can lead to headaches, constipation, tiredness and more serious problems, such as urinary infections and kidney disease. ... This could be a side effect of a condition such as stroke, motor neurone disease, multiple

More from intelligence
Approximately 0 fully matching, plus 31 partially matching documents found.

Latest appointments

  • Prevail Therapeutics adds to its board of directors Prevail Therapeutics adds to its board of directors

    The Prevail team has already made great progress in developing potential treatments for Parkinson’s disease and other neurodegenerative diseases, and I look forward to partnering with the team to help

  • Voyager Therapeutics appoints Matthew Ottmer as chief operating officer Voyager Therapeutics appoints Matthew Ottmer as chief operating officer

    He said: “I am thrilled to join Voyager at this important time during the company’s evolution. ... Developing and implementing the initial commercial strategy and planning for VY-AADC for Parkinson’s disease is a top priority, especially as we

  • Newron Pharma appoints commercial affairs VP Newron Pharma appoints commercial affairs VP

    He brings sales and marketing experience from Johnson &Johnson, and served as franchise marketing director for psychiatry, Parkinson's disease and migraine products at Novartis. ... future. “At the same time we welcome Dennis as a new member of

  • Voyager Therapeutics appoints chief financial officer Voyager Therapeutics appoints chief financial officer

    This strong foundation combined with the company's recent positive interim phase Ib data from its lead program VY-AADC01 for advanced Parkinson's disease and the opportunity to join a ... I am thrilled to join the Voyager team and meaningfully contribute

  • Pfizer appoints chief scientific officer Pfizer appoints chief scientific officer

    Having first joined Harvard in 1989, Dr Isacson's work in neurogenerative disorders, particularly for Parkinson's disease, has become internationally renowned with his laboratory now one of the leading academic ... s disease, where we are working to

More from appointments
Approximately 0 fully matching, plus 17 partially matching documents found.

Latest from PMHub

  • Robust Review: Vetting Evidence Generation Plan

    A client was interested in launching their product for an indication within Parkinson's disease.

  • September 2020: diversity and inclusion in clinical trials round-up September 2020: diversity and inclusion in clinical trials round-up

    Lack of awareness of clinical trials is a barrier faced by Hispanic people with Parkinson’s disease. ... A recent study looked into the barriers to participation in clinical trials faced by Hispanic people who have Parkinson’s disease.

  • Forging innovative solutions by merging art and science

    She studied neuroscience at the University of Toronto, worked in labs at Toronto’s Krembil Neuroscience Centre researching Parkinson’s disease and hippocampal neurogenesis, and was also a therapist in private ... practice. Ariel’s uncommon

  • The ALS patient journey

    Amyotrophic lateral sclerosis (ALS) is the most common form of motor neuron disease (MND). ... That will be the start of ALS, but your doctor will want to rule out other things, for example, Parkinson’s disease or multiple sclerosis.

  • The dark side of direct-to-consumer genetic tests

    Instead,   they interpret single-nucleotide polymorphisms (SNPs), and while SNPs can indicate a gene is associated with a disease, many are benign and have no impact on health. ... Who can blame them? If an email landed in your inbox that appeared to

More from PMHub
Approximately 0 fully matching, plus 9 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Empowering Strategic Performance Ltd

OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...